Moshe Ben-Shoshan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Moshe Ben-Shoshan has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Bruce D. Mazer
Division of Clinical and Translational Research, Department of Medicine, McGill University, Montreal, Canada
2 shared publications - Christine McCusker
Division of Allergy and Clinical Immunology, Department of Pediatrics, Montreal Children's Hospital, McGill University Health Centre, Montreal, QC, Canada
2 shared publications - Connor Prosty
Faculty of Medicine, McGill University, Montreal, Quebec, Canada
2 shared publications - Duncan Lejtenyi
Division of Allergy and Immunology, Department of Pediatrics, Montreal Children's Hospital, Montreal, Canada
2 shared publications - Edmond S. Chan
Division of Allergy, Department of Pediatrics, Faculty of Medicine, The University of British Columbia, Vancouver, BC, Canada; BC Children's Hospital Research Institute, Vancouver, BC, Canada
2 shared publications - Elena Netchiporouk
Division of Dermatology, Department of Medicine McGill University and McGill University Health Centre Montreal Quebec Canada
2 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
Shared Decision Making and Health-Related Quality of Life in Atopic Dermatitis and Chronic Urticaria
- 23 October 2026
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
Open AccessShared Decision Making and Health-Related Quality of Life in Atopic Dermatitis and Chronic Urticaria
- Open Access
- 17 February 2026
- Published by S. Karger AG in International Archives of Allergy and Immunology
- p. 1-13
Predictors of Fatal Anaphylaxis: A Systematic Review
Introduction: Fatal anaphylaxis is a rare but devastating outcome of severe allergic reactions. Identifying predictors of fatal anaphylaxis is essential to guide prevention, early intervention, education, and management strategies. Methods: A systematic review was conducted following Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. A comprehensive health sciences librarian-assisted search of MEDLINE, Embase, Cochrane Library, Scopus, and Web of Science identified studies published from inception to December 2024. Inclusion criteria encompassed observational studies and randomized controlled trials investigating fatal anaphylaxis in adults and children. Risk of bias was evaluated using the Joanna Briggs Institute (JBI) Critical Appraisal Tools. Results: A total of 3,006 studies were identified through five databases. After removing 1,038 duplicates, 1,968 unique records were screened. Of these, 136 full-text articles were assessed for eligibility, and 28 met the inclusion criteria. The included studies were conducted across 20 countries. Of the 28 included studies, 27 were retrospective cohort designs and one was a case-control study. This predominance of retrospective designs is expected given the rare and unpredictable nature of fatal anaphylaxis. Food allergens (particularly peanuts and cow’s milk), medications (e.g., antibiotics, contrast media, and neuromuscular blockers), and insect stings were the most common triggers of fatal anaphylaxis. Asthma, cardiovascular comorbidities, and older age (≥65 years) were frequently reported predictors of mortality. Delayed epinephrine administration defined as more than 30 min after symptom onset or failure to administer in the prehospital setting was also associated with fatal outcomes. Subgroup analyses identified higher risk among patients with multiple comorbidities and those exposed to high-risk allergens, including peanuts and cow’s milk in children (<18 years) and perioperative medications in older adults (≥65 years). Risk of bias analysis indicated moderate study quality, with limitations largely due to retrospective designs and inconsistent reporting. Conclusions: Asthma, cardiovascular comorbidities, older age, and delayed epinephrine administration were key predictors of fatal anaphylaxis. These findings highlight the need for timely intervention and targeted strategies, while emphasizing the importance of improved global data and standardized methodologies.
- 17 February 2026
- Published by S. Karger AG in International Archives of Allergy and Immunology
- p. 1-13
Open AccessPredictors of Fatal Anaphylaxis: A Systematic Review
Introduction: Fatal anaphylaxis is a rare but devastating outcome of severe allergic reactions. Identifying predictors of fatal anaphylaxis is essential to guide prevention, early intervention, education, and management strategies. Methods: A systematic review was conducted following Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. A comprehensive health sciences librarian-assisted search of MEDLINE, Embase, Cochrane Library, Scopus, and Web of Science identified studies published from inception to December 2024. Inclusion criteria encompassed observational studies and randomized controlled trials investigating fatal anaphylaxis in adults and children. Risk of bias was evaluated using the Joanna Briggs Institute (JBI) Critical Appraisal Tools. Results: A total of 3,006 studies were identified through five databases. After removing 1,038 duplicates, 1,968 unique records were screened. Of these, 136 full-text articles were assessed for eligibility, and 28 met the inclusion criteria. The included studies were conducted across 20 countries. Of the 28 included studies, 27 were retrospective cohort designs and one was a case-control study. This predominance of retrospective designs is expected given the rare and unpredictable nature of fatal anaphylaxis. Food allergens (particularly peanuts and cow’s milk), medications (e.g., antibiotics, contrast media, and neuromuscular blockers), and insect stings were the most common triggers of fatal anaphylaxis. Asthma, cardiovascular comorbidities, and older age (≥65 years) were frequently reported predictors of mortality. Delayed epinephrine administration defined as more than 30 min after symptom onset or failure to administer in the prehospital setting was also associated with fatal outcomes. Subgroup analyses identified higher risk among patients with multiple comorbidities and those exposed to high-risk allergens, including peanuts and cow’s milk in children (<18 years) and perioperative medications in older adults (≥65 years). Risk of bias analysis indicated moderate study quality, with limitations largely due to retrospective designs and inconsistent reporting. Conclusions: Asthma, cardiovascular comorbidities, older age, and delayed epinephrine administration were key predictors of fatal anaphylaxis. These findings highlight the need for timely intervention and targeted strategies, while emphasizing the importance of improved global data and standardized methodologies.
- Open Access
Comparative Analysis of Pediatric and Adult Mastocytosis: Clinical Presentation, Triggers, and Treatment Patterns from a Tertiary Care Registry
Background: Mastocytosis is a rare hematologic disorder, classified into cutaneous mastocytosis (CM) and systemic mastocytosis (SM). Understanding age-related differences in presentation and management is essential for individualized care. Methods: Data from patients recruited from the Montreal Children’s and Montreal General Hospitals between 2015 and 2024 were analyzed. Descriptive statistics were employed to present patient demographics, clinical characteristics, and medication usage. Statistical analyses included Fisher’s exact test for categorical variables and t-tests or non-parametric equivalents for continuous variables. Results: A total of 63 patients were included, comprising 39 children and 24 adults. Children had a median age of 1.9 years, while adults had a median age of 49.3 years. CM was exclusively prevalent in children (100.0%), while SM was more common in adults (45.8%). Adults with SM had a significantly higher median age than CM (49.4 versus 44.7 years, respectively, p = 0.03). Epinephrine use was more frequent in adult SM patients (36.4% versus 0%, respectively, p = 0.03). No pediatric patients required epinephrine for symptom control. Conclusions: This study highlights important clinical differences between pediatric and adult mastocytosis. CM was more common in children while SM predominated in adults and was associated with greater flare severity and higher tryptase levels.
Open AccessComparative Analysis of Pediatric and Adult Mastocytosis: Clinical Presentation, Triggers, and Treatment Patterns from a Tertiary Care Registry
Background: Mastocytosis is a rare hematologic disorder, classified into cutaneous mastocytosis (CM) and systemic mastocytosis (SM). Understanding age-related differences in presentation and management is essential for individualized care. Methods: Data from patients recruited from the Montreal Children’s and Montreal General Hospitals between 2015 and 2024 were analyzed. Descriptive statistics were employed to present patient demographics, clinical characteristics, and medication usage. Statistical analyses included Fisher’s exact test for categorical variables and t-tests or non-parametric equivalents for continuous variables. Results: A total of 63 patients were included, comprising 39 children and 24 adults. Children had a median age of 1.9 years, while adults had a median age of 49.3 years. CM was exclusively prevalent in children (100.0%), while SM was more common in adults (45.8%). Adults with SM had a significantly higher median age than CM (49.4 versus 44.7 years, respectively, p = 0.03). Epinephrine use was more frequent in adult SM patients (36.4% versus 0%, respectively, p = 0.03). No pediatric patients required epinephrine for symptom control. Conclusions: This study highlights important clinical differences between pediatric and adult mastocytosis. CM was more common in children while SM predominated in adults and was associated with greater flare severity and higher tryptase levels.
- 2 August 2025
Global Approach for Severe Cutaneous Adverse Reactions (GRASS) Survey.
Consensus guidelines outline the recommended management of delayed drug hypersensitivity reactions (DHR), but clinical practices are largely expert-based and may vary significantly across populations and regions. This study evaluated the approach and management of healthcare specialists globally regarding DHR, including severe cutaneous adverse reactions (SCARs). To assess the current practices, knowledge, and availability of allergy testing for DHR, including SCARs, among relevant healthcare professionals globally. The GRASS (Global AppRoAch for Severe Cutaneous Adverse Reactions Survey) study is a prospective, web-based survey conducted using the Research Electronic Data Capture (REDCap) platform. The 10- to 15-minute survey was directed to 14 allergy/immunology and dermatology associations through international mailing lists across 48 countries. Among the 8,561 members contacted, answers from 130 healthcare providers practicing in all six continents were analyzed. Most respondents identified as Caucasian (88/130; 68%) and female (79/130; 61%), representing a range of age groups and clinical expertise. Most practiced in dermatology (69/130; 53%), followed by allergy/immunology (46/130; 35.4%), and were based in an urban setting (127/130; 98%). Among the 45 respondents (34.6%) who managed SCARs, 27 (60%) had access to multidisciplinary care. Practices varied widely by clinical phenotype; for example, for maculopapular exanthema, 63 respondents indicated treating through the reaction (63/130; 49%), while 16 (16/130;12%) offered desensitization. Under patient education and follow-up, only 60 (60/130; 46.2%) participants organized a follow-up with the implicated specialist. Significant variability in the management of DHR was observed among the respondents. The results highlight the need for evidence-based protocols to standardize guidelines for managing DHRs.
- 2 August 2025
Global Approach for Severe Cutaneous Adverse Reactions (GRASS) Survey.
Consensus guidelines outline the recommended management of delayed drug hypersensitivity reactions (DHR), but clinical practices are largely expert-based and may vary significantly across populations and regions. This study evaluated the approach and management of healthcare specialists globally regarding DHR, including severe cutaneous adverse reactions (SCARs). To assess the current practices, knowledge, and availability of allergy testing for DHR, including SCARs, among relevant healthcare professionals globally. The GRASS (Global AppRoAch for Severe Cutaneous Adverse Reactions Survey) study is a prospective, web-based survey conducted using the Research Electronic Data Capture (REDCap) platform. The 10- to 15-minute survey was directed to 14 allergy/immunology and dermatology associations through international mailing lists across 48 countries. Among the 8,561 members contacted, answers from 130 healthcare providers practicing in all six continents were analyzed. Most respondents identified as Caucasian (88/130; 68%) and female (79/130; 61%), representing a range of age groups and clinical expertise. Most practiced in dermatology (69/130; 53%), followed by allergy/immunology (46/130; 35.4%), and were based in an urban setting (127/130; 98%). Among the 45 respondents (34.6%) who managed SCARs, 27 (60%) had access to multidisciplinary care. Practices varied widely by clinical phenotype; for example, for maculopapular exanthema, 63 respondents indicated treating through the reaction (63/130; 49%), while 16 (16/130;12%) offered desensitization. Under patient education and follow-up, only 60 (60/130; 46.2%) participants organized a follow-up with the implicated specialist. Significant variability in the management of DHR was observed among the respondents. The results highlight the need for evidence-based protocols to standardize guidelines for managing DHRs.
- 27 June 2024
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 12 (10) , 2811-2816.e2
Long-Term Adherence and Risk of Allergic Reactions in Patients Who Attained Milk Oral Immunotherapy Maintenance
- 27 June 2024
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 12 (10) , 2811-2816.e2
Long-Term Adherence and Risk of Allergic Reactions in Patients Who Attained Milk Oral Immunotherapy Maintenance
- Open Access
- 18 July 2023
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 19 (1) , 1-4
Early introduction is not enough: CSACI statement on the importance of ongoing regular ingestion as a means of food allergy prevention
- 18 July 2023
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 19 (1) , 1-4
Open AccessEarly introduction is not enough: CSACI statement on the importance of ongoing regular ingestion as a means of food allergy prevention
- Open Access
Food Allergy Education and Management in Schools: A Scoping Review on Current Practices and Gaps
Currently, no synthesis of in-school policies, practices and teachers and school staff’s food allergy-related knowledge exists. We aimed to conduct a scoping review on in-school food allergy management, and perceived gaps or barriers in these systems. We conducted a PRISMA-ScR-guided search for eligible English or French language articles from North America, Europe, or Australia published in OVID-MedLine, Scopus, and PsycINFO databases. Two reviewers screened 2010 articles’ titles/abstracts, with 77 full-text screened. Reviewers differed by language. Results were reported descriptively and thematically. We included 12 studies. Among teachers and school staff, food allergy experiences, training, and knowledge varied widely. Food allergy experience was reported in 10/12 studies (83.4%); 20.0–88.0% had received previous training (4/10 studies; 40.0%) and 43.0–72.2% never had training (2/10 studies; 20.0%). In-school policies including epinephrine auto-injector (EAI) and emergency anaphylaxis plans (EAP) were described in 5/12 studies (41.7%). Educational interventions (8/12 studies; 66.7%) increased participants’ knowledge, attitudes, beliefs, and confidence to manage food allergy and anaphylaxis vs. baseline. Teachers and school staff have more food allergy-related experiences than training and knowledge to manage emergencies. Mandatory, standardized training including EAI use and evaluation, and the provision of available EAI and EAPs may increase school staff emergency preparedness.
Open AccessFood Allergy Education and Management in Schools: A Scoping Review on Current Practices and Gaps
Currently, no synthesis of in-school policies, practices and teachers and school staff’s food allergy-related knowledge exists. We aimed to conduct a scoping review on in-school food allergy management, and perceived gaps or barriers in these systems. We conducted a PRISMA-ScR-guided search for eligible English or French language articles from North America, Europe, or Australia published in OVID-MedLine, Scopus, and PsycINFO databases. Two reviewers screened 2010 articles’ titles/abstracts, with 77 full-text screened. Reviewers differed by language. Results were reported descriptively and thematically. We included 12 studies. Among teachers and school staff, food allergy experiences, training, and knowledge varied widely. Food allergy experience was reported in 10/12 studies (83.4%); 20.0–88.0% had received previous training (4/10 studies; 40.0%) and 43.0–72.2% never had training (2/10 studies; 20.0%). In-school policies including epinephrine auto-injector (EAI) and emergency anaphylaxis plans (EAP) were described in 5/12 studies (41.7%). Educational interventions (8/12 studies; 66.7%) increased participants’ knowledge, attitudes, beliefs, and confidence to manage food allergy and anaphylaxis vs. baseline. Teachers and school staff have more food allergy-related experiences than training and knowledge to manage emergencies. Mandatory, standardized training including EAI use and evaluation, and the provision of available EAI and EAPs may increase school staff emergency preparedness.
- Open Access
- 2 March 2016
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 12 (1) , 10
T-cell receptor phenotype pattern in atopic children using commercial fluorescently labeled antibodies against 21 human class-specific v segments for the tcrβ chain (vβ) of peripheral blood: a cross sectional study
T-cell receptor (TCR) repertoire development is an integral part of the adaptive immune response. T-cell activation requires recognition of appropriately processed antigens by the TCR. Development of a diverse repertoire of TCRs is therefore essential to ensure adequate protection from potential threats. The majority of T-cells in peripheral blood have TCRs composed of an alpha and a beta chain. At the DNA level, the TCR genes are formed through directed recombination from germline sequences—the so-called VDJ recombination [variable (V) joining (J) diversity (D) gene segments] which results in variations in the repertoire. The most variable part of TCRs is the Vβ region (VβTCR), which has multiple V segment families that can be quantitatively measured. However, only sparse data exists on the normal levels of the VβTCR repertoire in healthy children. We aimed to establish normal values for the VβTCR repertoire in atopic children without immunodeficiency. Fifty-three children were recruited from food allergy, drug allergy, chronic urticaria and anaphylaxis registries and were divided into groups based on age: >0–2 years, 3–6 years, and 6–18 years. We used commercially available and fluorescently labeled antibodies against 21 human class-specific V segments of the TCRβ chain (Vβ) to study in peripheral blood the quantitative pattern of Vβ variation by flow cytometry. Children of all ages exhibited a similar pattern of TCR Vβ expression. Vβ 2 was the most commonly expressed family in all three age groups [9.5 % (95 % CI, 8.9, 10 %), 8.8 % (95 % CI, 7.4, 10.2 %) and 7.6 % (7.0, 8.3 %) respectively]. However, the percentage of Vβ 2 decreased in older children and the percentage of Vβ 1 was higher in males. TCR Vβ expression in our sample of atopic children did not differ substantially from previously published levels in non-atopic cohorts. TCR Vβ diversity follows a predictable and comparable pattern in atopic and healthy non-atopic children. Establishing normal levels for healthy children with and without atopy will contribute to a better definition of Vβ receptor deviation in children with primary immunodeficiency and/or immunodysregulation conditions.
- 2 March 2016
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 12 (1) , 10
Open AccessT-cell receptor phenotype pattern in atopic children using commercial fluorescently labeled antibodies against 21 human class-specific v segments for the tcrβ chain (vβ) of peripheral blood: a cross sectional study
T-cell receptor (TCR) repertoire development is an integral part of the adaptive immune response. T-cell activation requires recognition of appropriately processed antigens by the TCR. Development of a diverse repertoire of TCRs is therefore essential to ensure adequate protection from potential threats. The majority of T-cells in peripheral blood have TCRs composed of an alpha and a beta chain. At the DNA level, the TCR genes are formed through directed recombination from germline sequences—the so-called VDJ recombination [variable (V) joining (J) diversity (D) gene segments] which results in variations in the repertoire. The most variable part of TCRs is the Vβ region (VβTCR), which has multiple V segment families that can be quantitatively measured. However, only sparse data exists on the normal levels of the VβTCR repertoire in healthy children. We aimed to establish normal values for the VβTCR repertoire in atopic children without immunodeficiency. Fifty-three children were recruited from food allergy, drug allergy, chronic urticaria and anaphylaxis registries and were divided into groups based on age: >0–2 years, 3–6 years, and 6–18 years. We used commercially available and fluorescently labeled antibodies against 21 human class-specific V segments of the TCRβ chain (Vβ) to study in peripheral blood the quantitative pattern of Vβ variation by flow cytometry. Children of all ages exhibited a similar pattern of TCR Vβ expression. Vβ 2 was the most commonly expressed family in all three age groups [9.5 % (95 % CI, 8.9, 10 %), 8.8 % (95 % CI, 7.4, 10.2 %) and 7.6 % (7.0, 8.3 %) respectively]. However, the percentage of Vβ 2 decreased in older children and the percentage of Vβ 1 was higher in males. TCR Vβ expression in our sample of atopic children did not differ substantially from previously published levels in non-atopic cohorts. TCR Vβ diversity follows a predictable and comparable pattern in atopic and healthy non-atopic children. Establishing normal levels for healthy children with and without atopy will contribute to a better definition of Vβ receptor deviation in children with primary immunodeficiency and/or immunodysregulation conditions.